Compile Data Set for Download or QSAR
maximum 50k data
Found 37 Enz. Inhib. hit(s) with all data for entry = 11351
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609053(US11702411, Compound 28)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM575622((6-((2-amino-3-chloropyridin-4-yl)thio)-3- ((3S,4S...)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609051(US11702411, Compound 26 | {3-[(3S,4S)-4-amino-3-me...)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609050(US11702411, Compound 25)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609049(US11702411, Compound 24)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609048(US11702411, Compound 23)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609047(3-({5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4...)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609046(US11702411, Compound 21)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609057(US11702411, Compound 32)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609044(US11702411, Compound 19)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609052(US11702411, Compound 27)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609040(US11702411, Compound 15)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609054(US11702411, Compound 29)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608821((6-((2-amino-3-chloropyridin-4-yl)thio)-3-(4-amino...)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608966(US11702411, Compound 11)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609055(US11702411, Compound 30)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608866(US11702411, Compound 5 | [6-[(2-amino-3-chloro-4-p...)
Affinity DataIC50: <50nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608819(US11702411, Compound 2 | US11702411, Example 2)
Affinity DataIC50:  88nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608817(US11702411, Compound 1 | US11702411, Example 1)
Affinity DataIC50:  145nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609045(US11702411, Compound 20)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609043(US11702411, Compound 18)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609059(US11702411, Compound 35)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608993(US11702411, Compound 14)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608992(US11702411, Compound 13)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608960(US11702411, Compound 10 | {3-[(3S,4S)-4-amino-3-me...)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608959(US11702411, Compound 9)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608924(2-{5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4....)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608867(US11702411, Compound 6 | {3-[(3S,4S)-4-amino-3-met...)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608820(US11702411, Compound 3 | US11702411, Example 3)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608819(US11702411, Compound 2 | US11702411, Example 2)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608817(US11702411, Compound 1 | US11702411, Example 1)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609041(US11702411, Compound 16)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609058(US11702411, Compound 34)
Affinity DataIC50:  275nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608820(US11702411, Compound 3 | US11702411, Example 3)
Affinity DataIC50:  461nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608923(US11702411, Compound 7 | {3-[(3S,4S)-4-amino-3-met...)
Affinity DataIC50: >500nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM608967(US11702411, Compound 12)
Affinity DataIC50: >500nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Revolution Medicines

US Patent
LigandPNGBDBM609042(US11702411, Compound 17)
Affinity DataIC50: >500nMAssay Description:The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μM) was monitored using an assay in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent